528885-24-7

Basic information

• Product Name: 2-Furancarboxylic acid, 5-[3-[[[5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-1,2-dihydro-2-oxo-3H-1, 3,4-benzotriazepin-3-yl]acetyl]amino]phenyl]-
• CAS NO: 528885-24-7
• Molecular Formula: C33H36N4O6
• Molecular Weight: 584.672
• Mol File: 528885-24-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-Furancarboxylic acid, 5-[3-[[[5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-1,2-dihydro-2-oxo-3H-1, 3,4-benzotriazepin-3-yl]acetyl]amino]phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Furancarboxylic acid, 5-[3-[[[5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-1,2-dihydro-2-oxo-3H-1, 3,4-benzotriazepin-3-yl]acetyl]amino]phenyl]-(528885-24-7)
• EPA Substance Registry System: 2-Furancarboxylic acid, 5-[3-[[[5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-1,2-dihydro-2-oxo-3H-1, 3,4-benzotriazepin-3-yl]acetyl]amino]phenyl]-(528885-24-7)

Safety Data

• Hazardous Substances Data: 528885-24-7(Hazardous Substances Data)

Upstream product

• 942232-15-7 C₃₄H₃₈N₄O₆ 
• 528882-09-9 (5-cyclohexyl-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetic acid ethyl ester 
• 528882-12-4 (5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetic acid 
• 528882-11-3 (5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetic acid ethyl ester 
• 528882-08-8 (N'-((2-amino-phenyl)-cyclohexyl-methylene)-hydrazino)acetic acid ethyl ester 
• 13130-13-7 5-(3-nitro-phenyl)-furan-2-carboxylic acid 
• 54023-06-2 5-(3-amino-phenyl)-furan-2-carboxylic acid methyl ester 
• 41019-37-8 5-(3-nitrophenyl)-furan-2-carboxylic acid methyl ester 
• 3432-87-9 (2-aminophenyl)cyclohexylmethanone 
• 5469-26-1 1-Bromopinacolon 

Downstream Products

• 528885-25-8 5-(3-{2-[5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl]-acetylamino}-phenyl)-furan-2-carboxylic acid N-methyl-D-glucamine salt 

Relevant articles and documents

Optimization of 1,3,4-benzotriazepine-based CCK2 antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion

Starting from a novel, achiral 1,3,4-benzotriazepine-based CCK2 receptor antagonist, a process of optimization has afforded further compounds of this type that maintain the nanomolar affinity for recombinant, human CCK2 receptors and high selectivity over